Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1
VEVYE® is the First and Only Cyclosporine-Based Product Indicated for the Treatment of Both Signs and Symptoms of Dry Eye Disease with Efficacy Demonstrated After Four WeeksVEVYE® is the Only Water-Free Ophthalmic Product with Convenient Twice-Daily (BID) DosingNASHVILLE, Tenn. & HEIDELBERG, Germany--(BUSINESS WIRE)...
Source: pharmiweb.com
